The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
Hamburg
2022
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 172 Seiten Illustrationen, Diagramme 30 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV049588628 | ||
| 003 | DE-604 | ||
| 007 | t| | ||
| 008 | 240227s2022 gw a||| m||| 00||| eng d | ||
| 015 | |a 23,H09 |2 dnb | ||
| 016 | 7 | |a 1294379798 |2 DE-101 | |
| 020 | |c Festeinband | ||
| 035 | |a (OCoLC)1396209026 | ||
| 035 | |a (DE-599)DNB1294379798 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-355 | ||
| 084 | |8 1\p |a 610 |2 sdnb | ||
| 100 | 1 | |a Zarrer, Jennifer |d 1988- |e Verfasser |0 (DE-588)129511903X |4 aut | |
| 245 | 1 | 0 | |a The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |c vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst |
| 264 | 1 | |a Hamburg |c 2022 | |
| 300 | |a 172 Seiten |b Illustrationen, Diagramme |c 30 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |b Dissertation |c Universität Hamburg |d 2022 | ||
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 700 | 1 | |a Taipaleenmäki, Hanna |4 dgs | |
| 700 | 1 | |a Windhorst, Sabine |0 (DE-588)1027853730 |4 dgs | |
| 710 | 2 | |a Universität Hamburg |0 (DE-588)35534-3 |4 dgg | |
| 710 | 2 | |a Universität Hamburg |b Medizinische Fakultät |0 (DE-588)2109661-2 |4 oth | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u https://d-nb.info/1294379798/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034933355&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 883 | 2 | |8 1\p |a dnb |d 20230823 |q DE-101 |u https://d-nb.info/provenance/plan#dnb | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-034933355 | |
Datensatz im Suchindex
| _version_ | 1816446346107813888 |
|---|---|
| adam_text |
TABLE
OF
CONTENT
1
INTRODUCTION
.
11
1.1
BREAST
CANCER
.
11
1.2
BONE
.
12
1.2.1
BONE
PHYSIOLOGY.
12
1.2.2
WNT
SIGNALING
PATHWAY
.
14
1.3
BONE
MICROENVIRONMENT
.
16
1.3.1
OSTEOBLASTS
.
17
1.3.2
OSTEOCYTES
.
17
1.3.3
OSTEOCLASTS
.
18
1.3.4
ENDOTHELIAL
CELLS
.
19
1.3.5
ADIPOCYTES
.
22
1.3.6
IMMUNE
CELLS
.
24
1.4
SCLEROSTIN
.
25
1.4.1
DISEASES
ASSOCIATED
WITH
SCLEROSTIN
.
26
1.5
BONE
METASTASIS
.
27
1.5.1
CANCER-INDUCED
BONE
DISEASE
.
27
1.5.2
METASTATIC
CASCADE
.
27
1.5.3
VICIOUS
CYCLE
OF
BONE
METASTASIS.
29
1.5.4
BONE-CANCER
MICROENVIRONMENT.
29
1.6
TREATMENT
OF
METASTATIC
BONE
DISEASE
.
32
1.6.1.1
ANTI-RESORPTIVE
THERAPIES
.
32
1.6.1.1.1
BISPHOSPHONATES
.
32
1.6.1.2
DENOSUMAB
.
33
1.6.2
BONE
ANABOLIC
THERAPIES
.
34
1.6.2.1
PTH
ANALOGUES
.
34
1.6.2.2
ANTI-SCLEROSTIN
ANTIBODY
.
35
2
HYPOTHESIS
AND
AIMS
.
37
3
MATERIALS
UND
METHODS.
38
3.1
MATERIALS
.
38
3.1.1
CHEMICALS
AND
REAGENTS.
38
3.1.2
KITS
.
42
3.1.3
ANTIBODIES
AND
PRIMERS.
42
3.1.4
MACHINES.
44
3.1.5
SOFTWARES
.
45
3.2
METHODS
.
46
3.2.1
IN
VITRO
METHODS
.
46
3.2.1.1
CELL
LINES:
.
46
3.2.1.2
GENERAL
CELL
CULTURE:.
46
3.2.1.3
DETERMINATION
OF
CELL
NUMBER:
.
47
3.2.1.4
FREEZING
OF
CELLS:
.
47
3.2.1.5
THAWING
OF
CELLS:
.
47
3.2.1.6
COLLECTION
OF
(CANCER)
CONDITIONED
MEDIUM
((C)CM):
.
47
3.2.1.7
COLLECTION
OF
MURINE
BONE
MARROW
CELLS
(BMCS):
.
48
3.2.1.8
FLOW
CYTOMETRY:
.
49
3.2.1.9
MTS
ASSAY
.
49
3.2.1.10
TUBE
FORMATION
ASSAY
.
50
3.2.1.11
TRANSWELL
ASSAY
.
51
3.2.1.12
CHAMBER
SLIDES
.
53
3.2.1.13
DILC
LABELLING
OF
4T
1
-GFP-LUC
CELLS
.
54
3.2.2
IN
VIVO
METHODS
.
55
3
3.2.2.1
IN
VIVO
LABELING
WITH
FLUOROCHROMES
.
55
3.2.2.2
TREATMENT
WITH
ANTI-SCLEROSTIN
ANTIBODY
.
55
3.2.2.3
BIOLUMINESCENCE
IN
VIVO
IMAGING
AND
ANALYSIS
.
56
3.2.2.4
BLOOD/SERUM
.
56
3.2.2.5
ENZYME-LINKED
IMMUNOSORBENT
ASSAY
(ELISA)
.
57
3.2.3
MOLECULAR
BIOLOGY
.
57
3.2.3.1
RNA
EXTRACTION
OF
BONE
OR
SOFT
TISSUE
USING
HOMOGENIZER
.
57
3.2.3.2
RNA
EXTRACTION
USING
QIAGEN
KIT
.
58
3.2.3.3
ASSESSMENT
OF
RNA
CONCENTRATION
.
58
3.2.3.4
COMPLEMENTARY
DNA
(CDNA)
SYNTHESIS
.
58
3.2.3.5
QUANTITATIVE
POLYMERASE
CHAIN
REACTION
(QPCR)
.
59
3.2.3.6
ANALYSIS
OF
THE
RELATIVE
EXPRESSION
.
60
3.2.4
EX
VIVO
METHODS.
60
3.2.4.1
PREPARATION
OF
SOLUTIONS
FOR
HISTOLOGICAL
ANALYSIS
.
60
3.2.4.1
.1
4%
PARAFORMALDEHYDE
(PFA)
FOR
TISSUE
FIXATION
.
60
3.2.4.1
.2
4%
EDTA,
PH
7.0-7.4
.
60
3.2.4.1
.3
0.5M
EDTA,
PH
7.0-7.4
.
61
3.2.4.2
PROCESSING
AND
PARAFFIN
EMBEDDING
OF
BONES
.
61
3.2.4.3
PROCESSING
AND
PARAFFIN
EMBEDDING
OF
SOFT
TISSUE
.
61
3.2.4.4
PROCESSING
AND
PLASTIC
EMBEDDING
OF
LONG
BONES
.
62
3.2.4.5
PROCESSING
AND
GELATIN
EMBEDDING
OF
LONG
BONES
.
63
3.2.5
MICRO-COMPUTED
TOMOGRAPHY
(MICROCT)
.
64
3.2.5.1
SCANNING
OF
BONES
.
64
3.2.5.2
EVALUATION
OF
CANCELLOUS
BONE
.
64
3.2.5.3
EVALUATION
OF
CORTICAL
THICKNESS
.
66
3.2.6
STAININGS
.
66
3.2.6.1
HISTOLOGICAL
STAININGS
.
66
3.2.6.1.1
UNSTAINED
SECTIONS
.
66
3.2.6.1
.2
HEMALAUN
AND
EOSIN
(H&E)
.
67
3.2.6.1.3
VON
KOSSA/VAN
GIESON
STAINING
.
67
3.2.6.1
.4
TARTRATE-RESISTANCE
ACID
PHOSPHATASE
(TRAP)
STAINING
.
68
3.2.6.1.5
TOLUIDINE
BLUE
STAINING
.
69
3.2.6.1.6
OSX
AND
RFP
IMMUNOHISTOCHEMISTRY
.
70
3.2.6.1.7
ENDOMUCIN
IMMUNOHISTOCHEMISTRY
.
71
3.2.6.1.8
PERILIPIN
/
ENDOMUCIN
DOUBLE
STAINING
.
72
3.2.6.2
IMMUNOFLUORESCENCE.
74
3.2.7
HISTOLOGICAL
ANALYSIS
.
75
3.2.7.1
ANALYSIS
OF
TUMOR
AREA
PER
TISSUE
AREA
.
75
3.2.7.2
ANALYSIS
OF
ENDOMUCIN-POSITIVE
VASCULAR
CELLS
.
75
3.2.8
HISTOMORPHOMETRY
.
78
3.2.8.1
ANALYSIS
OF
MINERALIZED
BONE
.
78
1.1.1.1
DYNAMIC
HISTOMORPHOMETRY.
79
3.2.8.2
ANALYSIS
OF
TRAP
POSITIVE
CELLS
.
79
3.2.8.3
ANALYSIS
OF
TOLUIDINE
BLUE-POSITIVE
OSTEOBLASTS
.
80
3.2.8.4
ANALYSIS
OF
OSX-POSITIVE
CELLS
.
81
3.2.9
MICROSCOPY
.
81
3.2.10
STATISTICS
.
82
3.2.11
ETHICS
.
82
4
RESULTS
.
83
4.1
EFFECT
OF
RECOMBINANT
SOST
ON
OSTEOBLASTS,
ENDOTHELIAL
CELLS
AND
MOUSE
BREAST
CANCER
CELLS
IN
VITRO
.
83
4.2
EFFECT
OF
SCL-AB
SHORT-TERM
TREATMENT
ON
HEALTHY
BONE
MICROENVIRONMENT.
88
4.3
SCL-AB
-INDUCED
CHANGES
DO
NOT
AFFECT TUMOR
CELL
HOMING
.
98
4.4
EFFECT
OF
SCL-AB
SHORT-TERM
PRE-TREATMENT
ON
TUMOR
GROWTH
.
101
4.5
LONG-TERM
TREATMENT
WITH
SCL-AB
ALTERS
THE
BONE
MICROENVIRONMENT
.
106
4.6
LONG-TERM
TREATMENT
WITH
SCL-AB
DOES
NOT
ALTER TUMOR
CELL
HOMING
TO
BONE
.
114
4
4.7
BONE
ANABOLIC
SCL-AB
PRE-TREATMENT
ALTERS
BONE
MICROENVIRONMENT
AND
AFFECTS
TUMOR
GROWTH
.
117
5
DISCUSSION
.
130
5.1
EFFECT
OF
SCLEROSTIN
IN
VITRO
.
130
5.2
EFFECT
OF
SCLEROSTIN
INHIBITION
ON
BONE
CELLS
.
132
5.3
EFFECT
ON
ADIPOCYTES
.
133
5.4
EFFECT
ON
BONE
MARROW
VASCULATURE
AND
IMMUNE
CELLS
.
134
5.5
THE
ROLE
OF
THE
BONE
MARROW
MICROENVIRONMENT
ON
TUMOR
CELL
HOMING
.
135
5.6
CHANGES
IN
THE
TUMOR MICROENVIRONMENT
AND
TUMOR
GROWTH
.
137
6
CONCLUSION.
142
7
SUPPLEMENTS.
143
8
SUMMARY
.
150
8.1
SUMMARY
IN
ENGLISH
.
150
8.2
ZUSAMMENFASSUNG
AUF
DEUTSCH
.
151
9
ABBREVIATIONS
.
153
10
REFERENCES
.
157
11
ACKNOWLEDGEMENTS
.
166
12
CURRICULUM
VITAE
.
168
13
EIDESSTAATLICHE
ERKLARUNG
.
171
13.1
EIDESSTATTLICHE
VERSICHERUNG
.
171
13.2
DECLARATION
IN
ENGLISH
.
172
5 |
| adam_txt |
TABLE
OF
CONTENT
1
INTRODUCTION
.
11
1.1
BREAST
CANCER
.
11
1.2
BONE
.
12
1.2.1
BONE
PHYSIOLOGY.
12
1.2.2
WNT
SIGNALING
PATHWAY
.
14
1.3
BONE
MICROENVIRONMENT
.
16
1.3.1
OSTEOBLASTS
.
17
1.3.2
OSTEOCYTES
.
17
1.3.3
OSTEOCLASTS
.
18
1.3.4
ENDOTHELIAL
CELLS
.
19
1.3.5
ADIPOCYTES
.
22
1.3.6
IMMUNE
CELLS
.
24
1.4
SCLEROSTIN
.
25
1.4.1
DISEASES
ASSOCIATED
WITH
SCLEROSTIN
.
26
1.5
BONE
METASTASIS
.
27
1.5.1
CANCER-INDUCED
BONE
DISEASE
.
27
1.5.2
METASTATIC
CASCADE
.
27
1.5.3
VICIOUS
CYCLE
OF
BONE
METASTASIS.
29
1.5.4
BONE-CANCER
MICROENVIRONMENT.
29
1.6
TREATMENT
OF
METASTATIC
BONE
DISEASE
.
32
1.6.1.1
ANTI-RESORPTIVE
THERAPIES
.
32
1.6.1.1.1
BISPHOSPHONATES
.
32
1.6.1.2
DENOSUMAB
.
33
1.6.2
BONE
ANABOLIC
THERAPIES
.
34
1.6.2.1
PTH
ANALOGUES
.
34
1.6.2.2
ANTI-SCLEROSTIN
ANTIBODY
.
35
2
HYPOTHESIS
AND
AIMS
.
37
3
MATERIALS
UND
METHODS.
38
3.1
MATERIALS
.
38
3.1.1
CHEMICALS
AND
REAGENTS.
38
3.1.2
KITS
.
42
3.1.3
ANTIBODIES
AND
PRIMERS.
42
3.1.4
MACHINES.
44
3.1.5
SOFTWARES
.
45
3.2
METHODS
.
46
3.2.1
IN
VITRO
METHODS
.
46
3.2.1.1
CELL
LINES:
.
46
3.2.1.2
GENERAL
CELL
CULTURE:.
46
3.2.1.3
DETERMINATION
OF
CELL
NUMBER:
.
47
3.2.1.4
FREEZING
OF
CELLS:
.
47
3.2.1.5
THAWING
OF
CELLS:
.
47
3.2.1.6
COLLECTION
OF
(CANCER)
CONDITIONED
MEDIUM
((C)CM):
.
47
3.2.1.7
COLLECTION
OF
MURINE
BONE
MARROW
CELLS
(BMCS):
.
48
3.2.1.8
FLOW
CYTOMETRY:
.
49
3.2.1.9
MTS
ASSAY
.
49
3.2.1.10
TUBE
FORMATION
ASSAY
.
50
3.2.1.11
TRANSWELL
ASSAY
.
51
3.2.1.12
CHAMBER
SLIDES
.
53
3.2.1.13
DILC
LABELLING
OF
4T
1
-GFP-LUC
CELLS
.
54
3.2.2
IN
VIVO
METHODS
.
55
3
3.2.2.1
IN
VIVO
LABELING
WITH
FLUOROCHROMES
.
55
3.2.2.2
TREATMENT
WITH
ANTI-SCLEROSTIN
ANTIBODY
.
55
3.2.2.3
BIOLUMINESCENCE
IN
VIVO
IMAGING
AND
ANALYSIS
.
56
3.2.2.4
BLOOD/SERUM
.
56
3.2.2.5
ENZYME-LINKED
IMMUNOSORBENT
ASSAY
(ELISA)
.
57
3.2.3
MOLECULAR
BIOLOGY
.
57
3.2.3.1
RNA
EXTRACTION
OF
BONE
OR
SOFT
TISSUE
USING
HOMOGENIZER
.
57
3.2.3.2
RNA
EXTRACTION
USING
QIAGEN
KIT
.
58
3.2.3.3
ASSESSMENT
OF
RNA
CONCENTRATION
.
58
3.2.3.4
COMPLEMENTARY
DNA
(CDNA)
SYNTHESIS
.
58
3.2.3.5
QUANTITATIVE
POLYMERASE
CHAIN
REACTION
(QPCR)
.
59
3.2.3.6
ANALYSIS
OF
THE
RELATIVE
EXPRESSION
.
60
3.2.4
EX
VIVO
METHODS.
60
3.2.4.1
PREPARATION
OF
SOLUTIONS
FOR
HISTOLOGICAL
ANALYSIS
.
60
3.2.4.1
.1
4%
PARAFORMALDEHYDE
(PFA)
FOR
TISSUE
FIXATION
.
60
3.2.4.1
.2
4%
EDTA,
PH
7.0-7.4
.
60
3.2.4.1
.3
0.5M
EDTA,
PH
7.0-7.4
.
61
3.2.4.2
PROCESSING
AND
PARAFFIN
EMBEDDING
OF
BONES
.
61
3.2.4.3
PROCESSING
AND
PARAFFIN
EMBEDDING
OF
SOFT
TISSUE
.
61
3.2.4.4
PROCESSING
AND
PLASTIC
EMBEDDING
OF
LONG
BONES
.
62
3.2.4.5
PROCESSING
AND
GELATIN
EMBEDDING
OF
LONG
BONES
.
63
3.2.5
MICRO-COMPUTED
TOMOGRAPHY
(MICROCT)
.
64
3.2.5.1
SCANNING
OF
BONES
.
64
3.2.5.2
EVALUATION
OF
CANCELLOUS
BONE
.
64
3.2.5.3
EVALUATION
OF
CORTICAL
THICKNESS
.
66
3.2.6
STAININGS
.
66
3.2.6.1
HISTOLOGICAL
STAININGS
.
66
3.2.6.1.1
UNSTAINED
SECTIONS
.
66
3.2.6.1
.2
HEMALAUN
AND
EOSIN
(H&E)
.
67
3.2.6.1.3
VON
KOSSA/VAN
GIESON
STAINING
.
67
3.2.6.1
.4
TARTRATE-RESISTANCE
ACID
PHOSPHATASE
(TRAP)
STAINING
.
68
3.2.6.1.5
TOLUIDINE
BLUE
STAINING
.
69
3.2.6.1.6
OSX
AND
RFP
IMMUNOHISTOCHEMISTRY
.
70
3.2.6.1.7
ENDOMUCIN
IMMUNOHISTOCHEMISTRY
.
71
3.2.6.1.8
PERILIPIN
/
ENDOMUCIN
DOUBLE
STAINING
.
72
3.2.6.2
IMMUNOFLUORESCENCE.
74
3.2.7
HISTOLOGICAL
ANALYSIS
.
75
3.2.7.1
ANALYSIS
OF
TUMOR
AREA
PER
TISSUE
AREA
.
75
3.2.7.2
ANALYSIS
OF
ENDOMUCIN-POSITIVE
VASCULAR
CELLS
.
75
3.2.8
HISTOMORPHOMETRY
.
78
3.2.8.1
ANALYSIS
OF
MINERALIZED
BONE
.
78
1.1.1.1
DYNAMIC
HISTOMORPHOMETRY.
79
3.2.8.2
ANALYSIS
OF
TRAP
POSITIVE
CELLS
.
79
3.2.8.3
ANALYSIS
OF
TOLUIDINE
BLUE-POSITIVE
OSTEOBLASTS
.
80
3.2.8.4
ANALYSIS
OF
OSX-POSITIVE
CELLS
.
81
3.2.9
MICROSCOPY
.
81
3.2.10
STATISTICS
.
82
3.2.11
ETHICS
.
82
4
RESULTS
.
83
4.1
EFFECT
OF
RECOMBINANT
SOST
ON
OSTEOBLASTS,
ENDOTHELIAL
CELLS
AND
MOUSE
BREAST
CANCER
CELLS
IN
VITRO
.
83
4.2
EFFECT
OF
SCL-AB
SHORT-TERM
TREATMENT
ON
HEALTHY
BONE
MICROENVIRONMENT.
88
4.3
SCL-AB
-INDUCED
CHANGES
DO
NOT
AFFECT TUMOR
CELL
HOMING
.
98
4.4
EFFECT
OF
SCL-AB
SHORT-TERM
PRE-TREATMENT
ON
TUMOR
GROWTH
.
101
4.5
LONG-TERM
TREATMENT
WITH
SCL-AB
ALTERS
THE
BONE
MICROENVIRONMENT
.
106
4.6
LONG-TERM
TREATMENT
WITH
SCL-AB
DOES
NOT
ALTER TUMOR
CELL
HOMING
TO
BONE
.
114
4
4.7
BONE
ANABOLIC
SCL-AB
PRE-TREATMENT
ALTERS
BONE
MICROENVIRONMENT
AND
AFFECTS
TUMOR
GROWTH
.
117
5
DISCUSSION
.
130
5.1
EFFECT
OF
SCLEROSTIN
IN
VITRO
.
130
5.2
EFFECT
OF
SCLEROSTIN
INHIBITION
ON
BONE
CELLS
.
132
5.3
EFFECT
ON
ADIPOCYTES
.
133
5.4
EFFECT
ON
BONE
MARROW
VASCULATURE
AND
IMMUNE
CELLS
.
134
5.5
THE
ROLE
OF
THE
BONE
MARROW
MICROENVIRONMENT
ON
TUMOR
CELL
HOMING
.
135
5.6
CHANGES
IN
THE
TUMOR MICROENVIRONMENT
AND
TUMOR
GROWTH
.
137
6
CONCLUSION.
142
7
SUPPLEMENTS.
143
8
SUMMARY
.
150
8.1
SUMMARY
IN
ENGLISH
.
150
8.2
ZUSAMMENFASSUNG
AUF
DEUTSCH
.
151
9
ABBREVIATIONS
.
153
10
REFERENCES
.
157
11
ACKNOWLEDGEMENTS
.
166
12
CURRICULUM
VITAE
.
168
13
EIDESSTAATLICHE
ERKLARUNG
.
171
13.1
EIDESSTATTLICHE
VERSICHERUNG
.
171
13.2
DECLARATION
IN
ENGLISH
.
172
5 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Zarrer, Jennifer 1988- |
| author_GND | (DE-588)129511903X (DE-588)1027853730 |
| author_facet | Zarrer, Jennifer 1988- |
| author_role | aut |
| author_sort | Zarrer, Jennifer 1988- |
| author_variant | j z jz |
| building | Verbundindex |
| bvnumber | BV049588628 |
| ctrlnum | (OCoLC)1396209026 (DE-599)DNB1294379798 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000 c 4500</leader><controlfield tag="001">BV049588628</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">240227s2022 gw a||| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">23,H09</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1294379798</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="c">Festeinband</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1396209026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1294379798</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zarrer, Jennifer</subfield><subfield code="d">1988-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)129511903X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases</subfield><subfield code="c">vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hamburg</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">172 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield><subfield code="c">30 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Universität Hamburg</subfield><subfield code="d">2022</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taipaleenmäki, Hanna</subfield><subfield code="4">dgs</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Windhorst, Sabine</subfield><subfield code="0">(DE-588)1027853730</subfield><subfield code="4">dgs</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Universität Hamburg</subfield><subfield code="0">(DE-588)35534-3</subfield><subfield code="4">dgg</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Universität Hamburg</subfield><subfield code="b">Medizinische Fakultät</subfield><subfield code="0">(DE-588)2109661-2</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">https://d-nb.info/1294379798/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034933355&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="883" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">dnb</subfield><subfield code="d">20230823</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#dnb</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034933355</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV049588628 |
| illustrated | Illustrated |
| index_date | 2024-07-03T23:33:02Z |
| indexdate | 2024-11-22T17:57:07Z |
| institution | BVB |
| institution_GND | (DE-588)35534-3 (DE-588)2109661-2 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034933355 |
| oclc_num | 1396209026 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 172 Seiten Illustrationen, Diagramme 30 cm |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| record_format | marc |
| spelling | Zarrer, Jennifer 1988- Verfasser (DE-588)129511903X aut The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst Hamburg 2022 172 Seiten Illustrationen, Diagramme 30 cm txt rdacontent n rdamedia nc rdacarrier Dissertation Universität Hamburg 2022 (DE-588)4113937-9 Hochschulschrift gnd-content Taipaleenmäki, Hanna dgs Windhorst, Sabine (DE-588)1027853730 dgs Universität Hamburg (DE-588)35534-3 dgg Universität Hamburg Medizinische Fakultät (DE-588)2109661-2 oth B:DE-101 application/pdf https://d-nb.info/1294379798/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034933355&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p dnb 20230823 DE-101 https://d-nb.info/provenance/plan#dnb |
| spellingShingle | Zarrer, Jennifer 1988- The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| subject_GND | (DE-588)4113937-9 |
| title | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| title_auth | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| title_exact_search | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| title_exact_search_txtP | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| title_full | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst |
| title_fullStr | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst |
| title_full_unstemmed | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases vorgelegt von: Jennifer Zarrer ; Prüfungsausschuss, der/die Vorsitzende: Prof. Dr. Hanna Taipaleenmäki, Prüfungsausschuss, zweite/r Gutachter/in: Prof. Dr. Sabine Windhorst |
| title_short | The effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| title_sort | the effect of sclerostin inhibition on bone microenvironment and breast cancer bone metastases |
| topic_facet | Hochschulschrift |
| url | https://d-nb.info/1294379798/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034933355&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT zarrerjennifer theeffectofsclerostininhibitiononbonemicroenvironmentandbreastcancerbonemetastases AT taipaleenmakihanna theeffectofsclerostininhibitiononbonemicroenvironmentandbreastcancerbonemetastases AT windhorstsabine theeffectofsclerostininhibitiononbonemicroenvironmentandbreastcancerbonemetastases AT universitathamburg theeffectofsclerostininhibitiononbonemicroenvironmentandbreastcancerbonemetastases AT universitathamburgmedizinischefakultat theeffectofsclerostininhibitiononbonemicroenvironmentandbreastcancerbonemetastases |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis